Media & Resources

IAVI is saddened by the passing of Philip Russell, M.D., a committed global health leader and founding member of this organization.

Results illuminate potential way forward for use of broadly neutralizing antibodies to prevent HIV.

IAVI to participate in major HIV prevention research conference beginning January 27.

IAVI recognizes the European & Developing Countries Clinical Trials Partnership (EDCTP) for its continued commitment to supporting Europe and sub-Saharan Africa research collaborations and capacity building that work to accelerate the development and uptake of new and improved clinical interventions to combat HIV/AIDS, tuberculosis, and other infectious and neglected diseases.

This World AIDS Day, 2020 AVAC Advocacy Fellow Winifred Ikilai shares her a community perspective on the need to ensure globally accessible tools to end the HIV epidemic.

IAVI welcomes evidence of long-acting cabotegravir’s safety and efficacy in cisgender women.

The study will assess the safety, tolerability, and immunogenicity of SARS-CoV-2 vaccine candidate V590 compared to placebo.

There are more than 70 different mAbs in various stages of development for the treatment and prevention of COVID-19, including those discovered by a team of scientists including investigators from IAVI and Scripps Research.